<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00169221</url>
  </required_header>
  <id_info>
    <org_study_id>GORTEC 2004-02</org_study_id>
    <nct_id>NCT00169221</nct_id>
  </id_info>
  <brief_title>Post-operative Radiotherapy With Cisplatin Alone or in Combination With Iressa in Upper Aerodigestive Tract Carcinomas</brief_title>
  <official_title>CARISSA Trial - Multicenter Randomized Phase II Trial Comparing Post-operative Radiotherapy and Cisplatin Alone or in Combination With the EGFR Inhibitor ZD 1839 (Iressa) in Upper Aerodigestive Tract Carcinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Oncologie Radiotherapie Tete et Cou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Oncologie Radiotherapie Tete et Cou</source>
  <brief_summary>
    <textblock>
      This trial will be an open multicentric randomized phase II study comparing post-operative
      radiotherapy + cisplatin associated or not with Iressa in upper aerodigestive tract
      carcinomas.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Toxicity in an independent study IMEX. The trial was subsequently terminated (54 pts instead of
    140) despite safety analyses showing no excess of toxicity
  </why_stopped>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>postop chemoradio with cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>postoperative chemoradiotherapy with cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>postop chemoradio (cisplatin)+gefitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>postoperative chemoradiotherapy with cisplatin + gefitinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iressa (Gefitinib)</intervention_name>
    <description>postoperative chemoradiotherapy with cisplatin + gefitinib</description>
    <arm_group_label>postop chemoradio (cisplatin)+gefitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>chemoradiotherapy with cisplatin</intervention_name>
    <description>postoperative chemoradiotherapy with cisplatin</description>
    <arm_group_label>postop chemoradio with cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with upper aerodigestive tract carcinomas (all sites included) having
             surgical resection and eligible for post-operative radiation + cisplatin.

          -  Patient having a tumoral biopsy (0.5 - 1 cm3) stored in liquid nitrogen at time of
             surgical resection (patients with small tumors located in larynx for instance will not
             be included)

          -  Patients receiving post-operative radiation (&gt;=60 Gy on tumor bed and/or cervical
             area), associated with cisplatin, 6 weeks after surgery at the latest.

        Exclusion Criteria:

          -  previous history of cancer (except skin basal cell carcinoma)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rene-Jean Bensadoun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Antoine Lacassagne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>November 14, 2011</last_update_submitted>
  <last_update_submitted_qc>November 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

